Company / Shareholders' Equity
Oruka Therapeutics, Inc. Shareholders' Equity History
FY2015-FY2024 · Annual data · Source: SEC filings
At a glance
Latest annual filing availableLatest Shareholders' Equity
$1.0K
FY2024
5-year range
$1.0K / $51.0M
FY2020-FY2024
Trend
-100.0%
vs FY2023
Sector context
#191 of 213
Health Care
What the data says
Among 213 Health Care companies, Oruka Therapeutics, Inc. is in the bottom 10% for shareholders' equity. Shareholders' Equity has fluctuated over the past 10 years, ranging from $1,000 in FY2024 to $51M in FY2022.
Based on SEC 10-K filings.
$1,000 in FY2024 with a 5-year CAGR of -82.5%.
Declined from $51M to $1,000 over the past 2 years.
Health Care sector context is included.
Shareholders' Equity over time
Growth rates
- 3-Year CAGR
- -97.2%
- 5-Year CAGR
- -82.5%
- 10-Year CAGR
- -
Sector benchmark
Bottom 10% in Health CareTop 90% of 213This company $1.0K Sector average $2.5B
▼
-100.0% below sector average
Key checks
Key Insights
- 5-year CAGR of -82.5%, indicating a declining trend.
- In FY2024, shareholders' equity decreased 100.0% year-over-year.
- Ranks #191 out of 213 companies in the Health Care sector.
- Peak shareholders' equity was recorded in FY2022.
Company context
Key Data Points
- Low Piotroski F-Score: 1/9 (multiple financial health concerns)
- High earnings quality (cash-backed earnings)
Data sourced from SEC EDGAR filings. Not investment advice.
Annual data
| Year | Shareholders' EquityValue | YoY GrowthYoY |
|---|---|---|
| FY2024 | $1.0K | -100.0% |
| FY2023 | $37.0M | -27.5% |
| FY2022 | $51.0M | +9.7% |
| FY2021 | $46.5M | +511.3% |
| FY2020 | $7.6M | +26.2% |
| FY2019 | $6.0M | -41.3% |
| FY2018 | $10.3M | -53.7% |
| FY2017 | $22.2M | -41.7% |
| FY2016 | $38.1M | +158.3% |
| FY2015 | $14.7M | -5.4% |
As of FY2024 · SEC 10-K · Updated Jun 30, 2026